Abstract:Background OX40/OX40 ligand (OX40/OX40L) and programmed death-1/programmed death ligand-1 (PD-1/PD-L1) costimulatory signals play important roles in T cell-induced immune responses. The aim of this study was to investigate the roles of OX40/OX40L and PD-1/PD-L1 costimulatory pathways in mouse islet allograft rejection.Methods Lentiviral vectors containing OX40L siRNA sequences and an adenovirus vector containing the PD-L1 gene were constructed. The streptozotocin-induced model of diabetes was established in C57BL/6 (H-2(b)) mice. Diabetic C57BL/6 mice were randomly allocated into five groups: group 1, untreated control; group 2, Ad-EGFP treatment; group 3, Ad-PD-L1 treatment; group 4, OX40L-RNAi-LV treatment; group 5, OX40L-RNAi-LV combined with Ad-PD-L1 treatment. Lentiviral vector and the adenovirus vector were injected, singly or combined, into the caudal vein one day before islet transplantation. The islets of DBA/2 (H-2(d)) mice were transplanted into the renal subcapsular space of the diabetic recipients. Recipient blood glucose and the survival time of the allografts were monitored. Antigen-specific mixed lymphocyte reaction was also evaluated.Results The recombinant lentiviral RNA interference vector OX40L-RNAi-LV reduced OX40L protein expression by 70%. The recombinant adenovirus vector Ad-PD-L1 increased PD-L1 protein expression in vivo in C57BL/6 recipient mice. Combined OX40L-RNAi-LV/Ad-PD-L1 treatment induced a synergistic protective effect in pancreatic islet allografts. Allograft survival time in the combined treatment group was (92.27+/-9.65) days, not only longer than that of the control ((6.51+/-0.27) days) and Ad-EGFP groups ((7.09+/-0.13) days) (P<0.01), but also significantly longer than that of Ad-PD-L1 and OX40L-RNAi-LV single treatment groups ((40.64+/-3.95) days and (55.14+/-5.48) days respectively, P<0.01). The blood glucose concentration of recipient mice in the combined treatment group was also stable and kept within the normal range. Flow cytometry analysis showed that combined OX40L-RNAi-LV/Ad-PD-L1 treatment significantly decreased proliferation in an antigen-specific mixed lymphocyte reaction. After donor DBA/2 lymphocyte stimulation, 89.71% of lymphocytes from recipient combination treatment C57BL/6 mice were not split and proliferated. In contrast, after stimulation with third party Lewis rat lymphocytes, only 45.84% lymphocytes of C57BL/6 mice were not split and proliferated.Conclusions This study demonstrates the successful construction of the recombinant lentivirus vector OX40L-RNAi-LV and adenovirus vector Ad-PD-L1 for the blockade of OX40/OX40L and activation of PD-1/PD-L1 costimulatory pathways simultaneously in pancreatic islet allografts in diabetic mice. Combination therapy with these two vectors resulted in inhibition of T cell activation, synergistically prolonging the survival time of pancreatic islet allografts.

201.1: Co-engineering Pancreatic Islets with Novel Forms of Thrombomodulin and CD47 As an Effective Means of Mitigating Instant Blood-Mediated Inflammatory Reaction

Engineering Pancreatic Islets to Transiently Codisplay on Their Surface Thrombomodulin and CD47 Immunomodulatory Proteins as a Means of Mitigating Instant Blood-Mediated Inflammatory Reaction following Intraportal Transplantation

APT070 (mirococept), a membrane-localizing C3 convertase inhibitor, attenuates early human islet allograft damage in vitro and in vivo in a humanized mouse model

Co-transplantation of Islets-Laden Microgels and Biodegradable O2-Generating Microspheres for Diabetes Treatment

A novel prevascularized tissue-engineered chamber as a site for allogeneic and xenogeneic islet transplantation to establish a bioartificial pancreas

A bioengineered artificial interstitium supports long-term islet xenograft survival in nonhuman primates without immunosuppression

Innovations in bio-engineering and cell-based approaches to address immunological challenges in islet transplantation

Enhanced function of immuno-isolated islets in diabetes therapy by co-encapsulation with an anti-inflammatory drug.

Coatting NICCs with MSCs and EPCs to Alleviate Instant Blood-Mediated Inflammatory Reaction.

Advancements in innate immune regulation strategies in islet transplantation

Cd4(+)Cd25(+) Regulatory T-Cells Inhibit the Islet Innate Immune Response and Promote Islet Engraftment

Mechanism for the Instant Blood-Mediated Inflammatory Reaction in Rat Islet Transplantation.

Blockade of the OX40/OX40L Pathway and Induction of PD-L1 Synergistically Protects Mouse Islet Allografts from Rejection.

Probucol Pharmacological and Bio-Nanotechnological Effects on Surgically Transplanted Graft Due to Powerful Anti-Inflammatory, Anti-Fibrotic and Potential Bile Acid Modulatory Actions

Knockdown of Intraislet IKKβ by Spherical Nucleic Acid Conjugates Prevents Cytokine-Induced Injury and Enhances Graft Survival

Inflammation-induced subcutaneous neovascularization for the long-term survival of encapsulated islets without immunosuppression

The Fate of Allogeneic Pancreatic Islets following Intraportal Transplantation: Challenges and Solutions

Adipose Tissue-Derived Mesenchymal Stromal Cells Modulate Inflammatory Response and Improve Allograft Islet Transplant in Mice Model of Type 1 Diabetes

Rapid and Long‐Term Glycemic Regulation with a Balanced Charged Immune‐Evasive Hydrogel in T1DM Mice

Cellular Immune Responses in Islet Xenograft Rejection

Impact of Prevascularization on Immunological Environment and Early Engraftment in Subcutaneous Islet Transplantation